Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1500 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
Biotech Daily Editorial: Covid-19 Spruikers, Please Stop ! Dr Boreham's Crucible: Emvision Medical Devices Zelira: Marijuana ZLT-101 'Effective For Insomnia' FDA Clears Mesoblast Remestemcel-L For Covid-19 ARDS Biotech Daily Editorial: Covid-19 Coronavirus Claims Dr Boreham's Crucible Special: Covid-19 Biotech Daily Editorial: 2019-nCoV Coronavirus (Covid-19) All The Dope On Medicine, Marijuana, Cannabis & Hemp FDA Okays Redhill Talicia (Sydney's Heliconda) For H. Pylori Clinuvel Up 63% On FDA Scenesse For EPP Approval
Biotech Full Recovery: May BDI-40 Up 14% ASX200 Up 4%, Big Caps Down 6% YTD: BDI-40 Up 46%, Big Caps Up 40%, ASX200 Down 10%
June 1, 2020 The Biotech Daily Top-40 Index (BDI-40) recovered all of its Covid-19 pandemic global downturn in May, up 14.2 percent to $16,106 million - its second-best after the February pre-Covid-19 record high.
The benchmark ASX-200 was up 4.2 percent in May, but down 10.0 percent compared to May 31, 2019.
The collective market capitalization of the three Big Caps fell 6.0 percent in May, dragged down by CSL’s 8.9 percent retreat to just $130,544 million, its lowest market capitalization in five months and only 41.5 percent better than 12 months ago. Cochlear was up 8.5 percent in May to $12,708 million, with Resmed up 1.4 percent to $34,102 million.
For the year to May 31, the BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) climbed 46.3 percent, the three Big Caps were up 39.7 percent, with the ASX down 10.0 percent compared to May 31, 2019.
Thirty-four of the BDI-40 companies were up (23 by more than 10 percent and 13 by more than 20 percent), five fell (two by more than 10 percent) and one was unchanged.
In the BDI-20, 18 were up, one fell and one was unchanged.
Paradigm was the May BDI-20 best, up $231 million or 54.9 percent to $652 million, followed by Immutep (34.3%), Mesoblast (26.2%), Polynovo (25.7%), Opthea (25.2%), Cyclopharm (18.4%), Volpara (15.3%), Neuren (12.7%) and Pro Medicus (12.2%).
Recovering from much lower bases, the Second 20 was led by Osprey up 260.0 percent or $13 million to $18 million, followed by Impedimed (105.1%), Amplia (80%), Antisense (56.5%), LBT (48%), Resonance (33.3%), Imugene (31.25%), Dimerix (28.6%), Kazia (22.2%), Optiscan (16.7%), Alterity (11.8%) Universal Biosensors (11.4%), Prescient (11.1%) and Proteomics (10.7%).
Next Science led the very few falls in the BDI-40, down $65 million or 19.8 percent to $264 million, followed by Ellex (19.3%), Actinogen (8.7%), Patrys (6.7%) and Uscom (2.9%).
The 21 companies in Cannabis Corner climbed 5.2 percent in May, but were still 53.1 percent lower than May 31, 2019 and 56.6 percent or $1,080 million below their July 31, 2019 peak of $1,909 million.
Outside the BDI-40, Recce was up 88.9 percent to $102 million, Imagion was up 81.8 percent to $20 million, followed by Invex (69.2%) and Medadvisor (35.1%).
The Nasdaq Biotechnology Index was up 8.5 percent to 4,230 points in the month of May and up 34.8 percent for the 12 months to May 31, 2020.
The Brisbane and California based Protagonist jumped 148.6 percent to a record high of $711 million on news of a small study supporting PTG-300 for the blood cancer polycythemia vera (see article below). Redhill with Australian assets was up 1.9 percent to $377 million and Eyepoint (formerly Psivida) fell 13.4 percent to $161 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to May 31, 2020
 3-Year Big Caps (Cochlear, CSL, Resmed) to May 31, 2020
 BDI-40 ($m) v S&P ASX200 – Year to May 31, 2020
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At May 31, 2020
* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear
Cynata, Mesoblast, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in.